Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection

Meridian Bioscience

Status and phase

Completed

Phase 3

Conditions

Helicobacter Pylori Infection

Treatments

Device: Dual Mode BreathID Hp System

Study type

Interventional

Funder types

Industry

Identifiers

NCT02528721

DM2-HP-0715

Details and patient eligibility

About

The Exalenz Dual Mode BreathID® Hp System comprised of IDkit: Hp™ TWO and the Dual Mode BreathID® Hp test device will be used to perform a urea breath test in the initial diagnosis and post treatment monitoring of H.pylori infection in adult patients and its results will be compared to biopsy results.

Full description

Patients undergoing esophagogastroduodenoscopy (EGD) for initial diagnosis of H.pylori infection or post therapy confirmation of eradication will be eligible to participate in the trial. Two sets of biopsies will be taken: one set for histological analysis and one set for rapid urease test (RUT) analysis. The two results will be used as a gold standard composite score in determining the presence of H.pylori bacteria in the stomach. The Urea Breath Test (UBT) using the Exalenz Dual Mode BreathID Hp System will also be performed within a week of the biopsy. The outcome of the UBT will be compared to composite score of the biopsy and the accuracy of the UBT will be evaluated. The UBT will be performed using breath collection bags, where the subject will be asked to breathe into the bags before and after ingestion of the 13C-labelled urea.

Enrollment

282 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Be at least 18 years of age.
Have the ability and willingness to sign the Informed Consent Form.
Present with clinical indication of H. pylori and a candidate for upper endoscopy

For Initial Diagnosis arm:

• Symptomatic patients naïve to H.pylori treatment in the past 18 months

For Post-Therapy arm:

Documented biopsy with positive outcome prior to eradication therapy (including method of determination)
Documented eradication therapy within the past 6 months and completed at least 6 weeks prior to UBT

Exclusion criteria

Participation in other interventional trials.
- Antibiotics and/or Bismuth preparations within four (4) weeks prior to breath test.
- PPI or H2 blockers within two (2) weeks prior to breath test.
- Pregnant or breastfeeding women.
- Allergy to test substrates.
- Patient did not fast for the hour prior to the UBT